Stewart B Harris (Stewart Harris)

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 16

Top Topics

Glycemic Control

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

JMIR research protocols

JMIR medical education

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandria A Ratzki-Leewing, Jason E Black, Angelica Cristello Sarteau, Bridget L Ryan, Guangyong Zou, Neil Klar, Kristina Timcevska, Stewart B Harris
Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States). Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, John White, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, Maureen Carlyle, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Shannon Idzik, Adriano Boasso, Sola Quasheba Neunie, Alexander Daniel Noble, Helen Elaine Such, Joanna Van
The Educational Impact of Web-Based, Faculty-Led Continuing Medical Education Programs in Type 2 Diabetes: A Survey Study to Analyze Changes in Knowledge, Competence, and Performance of Health Care Professionals. JMIR medical education 8 (4) (2022)
Alexandria A Ratzki-Leewing, Jason E Black, Bridget L Ryan, Stewart B Harris
Real-world risk factors of confirmed or probable COVID-19 in Americans with diabetes: A prospective, community-based study (iNPHORM). Endocrinology, diabetes & metabolism 5 (4) (2022)
Alexandria A Ratzki-Leewing, Bridget L Ryan, Guangyong Zou, Susan Webster-Bogaert, Jason E Black, Kathryn Stirling, Kristina Timcevska, Nadia Khan, J Daniel Buchenberger, Stewart B Harris
Predicting Real-world Hypoglycemia Risk in American Adults With Type 1 or 2 Diabetes Mellitus Prescribed Insulin and/or Secretagogues: Protocol for a Prospective, 12-Wave Internet-Based Panel Survey With Email Support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study). JMIR research protocols 11 (2) (2022)
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Ulagamadesan Venkatesan, Stewart B Harris, Irene Hramiak, John Stewart, Lawrence Alan Leiter
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Ulagamadesan Venkatesan, Stewart B Harris, Irene Hramiak, John Stewart, Lawrence Alan Leiter
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Ulagamadesan Venkatesan, Stewart B Harris, Irene Hramiak, John Stewart, Lawrence Alan Leiter
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders 14 (2) (2022)
Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Ulagamadesan Venkatesan, Stewart B Harris, Irene Hramiak, John Stewart, Lawrence Alan Leiter
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
Alexandria A Ratzki-Leewing, Bridget L Ryan, John D Buchenberger, Joseph W Dickens, Jason E Black, Stewart B Harris
COVID-19 hinterland: surveilling the self-reported impacts of the pandemic on diabetes management in the USA (cross-sectional results of the iNPHORM study). BMJ open 11 (9) (2021)
Stewart B Harris, Olubukola Ajala, Basel Bari, Joanne Liutkus, Jina Hahn, Oliver Martyn, Deborah Zwicker
Evaluating the Effectiveness of Switching to Insulin Degludec from Other Basal Insulins in a Real-World Canadian Population with Type 1 or Type 2 Diabetes: The CAN-TREAT Study. Diabetes therapy : research, treatment and education of diabetes and related disorders 12 (6) (2021)
Stewart B Harris, Martin J Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard Ian Gregory Holt, Nóra Hosszúfalusi, Guy E H M Rutten, Tina Vilsbøll
Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs 80 (2) (2020)
Athena Philis-Tsimikas, Liana K Billings, Robert Busch, Cristobal Morales Portillo, Rakesh Sahay, Natalie Halladin, Sarah Eggert, Kamilla Begtrup, Stewart B Harris
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 21 (6) (2019)
Brian M Frier, Alexandria Ratzki-Leewing, Stewart B Harris
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus. Diabetes, obesity & metabolism 21 (7) (2019)
Stewart B Harris, Győző Kocsis, Rudolf Prager, Terry Ridge, Keval Chandarana, Natalie Halladin, Serge Jabbour
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes, obesity & metabolism 19 (6) (2017)